The company's Activated Bacterial Therapeutics (ABT) platform is designed to improve the delivery of microbiome therapeutics, with a focus on healing diseases associated with the central nervous system and gastrointestinal tract. By using a synbiotic-activated formulation, Scioto's platform primes therapeutic bacteria for optimized function in the GI. Their lead program, SB-121, has shown promising results in animal models, increasing oxytocin levels and improving GI survival and mucosal thickening in severe gut injury cases. As an early-stage biotech company, Scioto is dedicated to innovative research, discovery, and development in the field of microbiome therapeutics.